Elucidating the potential mechanisms involved in the detrimental effect of excess body weight on insulin action is an important priority in counteracting obesityassociated diseases. The present study aimed to disentangle the epigenetic basis of insulin resistance by performing a genome-wide epigenetic analysis in visceral adipose tissue (VAT) from morbidly obese patients depending on the insulin sensitivity evaluated by the clamp technique. The global human methylome screening performed in VAT from 7 insulin-resistant (IR) and 5 insulin-sensitive (IS) morbidly obese patients (discovery cohort) analyzed using the Infinium HumanMethylation450 BeadChip array identified 982 CpG sites able to perfectly separate the IR and IS samples. The identified sites represented 538 unique genes, 10% of which were diabetes-associated genes. The current work identified novel IR-related genes epigenetically regulated in VAT, such as COL9A1, COL11A2, CD44, MUC4, ADAM2, IGF2BP1, GATA4, TET1, ZNF714, ADCY9, TBX5, and HDACM. The gene with the largest methylation fold-change and mapped by 5 differentially methylated CpG sites located in island/shore and promoter region was ZNF714. This gene presented lower methylation levels in IR than in IS patients in association with increased transcription levels, as further reflected in a validation cohort (n 5 24; 11 IR and 13 IS). This study reveals, for the first time, a potential epigenetic regulation involved in the dysregulation of VAT that could predispose patients to insulin resistance and future type 2 dia-
INTRODUCTION
Insulin resistance refers to the inability of insulin to regulate systemic glucose metabolism. This condition is known to play a major role in the deleterious metabolic features associated with excess body weight. 1 As an underlying pathophysiological factor linked to the metabolic syndrome, 2 insulin resistance increases the risk of all causes of cancer and cardiovascular disease mortality. 3, 4 Among the mediators of insulin resistance associated with obesity, visceral adipose tissue (VAT) appears to play a relevant role in the development and maintenance of this disturbance. The amount of VAT has been shown to be the best predictor of insulin resistance measured by the clamp technique, [5] [6] [7] and it showed the strongest correlation with HOMA-IR according to a recent meta-analysis. 8 This is because the dysfunctional visceral adipose tissue associated with obesity secretes several factors that play relevant roles in obesity and obesity-related comorbidities. 9 However, the specific mechanism by which VAT becomes dysfunctional in promoting obesity-related complications, such as insulin resistance, must be fully disclosed.
Insulin resistance is known to be modulated by both genetic and environmental influences. 10 The interaction between these factors in the disease development can be mediated by epigenetic modifications. Epigenetic markers might explain the link between lifestyle and the risk of disease and have been proposed to be sensitive biomarkers and potential therapeutic targets for disease management. 11 Among epigenetic mechanisms, DNA methylation is the best studied epigenetic regulatory mechanism. DNA methylation has been proposed as a next-generation biomarker with great diagnostic and prognostic promise for clinicians. 12 In this context, previous studies have explored epigenetic involvement in obesity. 13 Moreover, the methylome of human pancreatic islets associated with type 2 diabetes (T2D) has been characterized, demonstrating that altered DNA methylation in human islets contributes to perturbed hormone secretion and the pathogenesis of T2D.
14 Furthermore, DNA methylation levels in adipose tissue have been related to alterations in glucose metabolism. 15 Differences in the methylation levels of VAT have also been identified by comparing patients with and without metabolic syndrome through a genome-wide differential methylation analysis. 16 However, the methylome of VAT has not been explored until now in insulin-resistant (IR) patients classified by the clamp technique, the gold-standard method for evaluating insulin sensitivity. 17 The present study aimed to disentangle the epigenetic basis of insulin resistance by performing a genomewide epigenetic analysis in VAT from morbidly obese patients depending on the insulin sensitivity evaluated by the clamp technique.
SUBJECTS AND METHODS
Study participants. A group of morbidly obese Caucasian patients (n 5 36) with different degrees of insulin AT A GLANCE COMMENTARY Crujeiras AB, et al.
Background
Because epigenetic modifications are dynamic, reversible, and change in response to several environmental factors, epigenetic markers related to insulin resistance may represent therapeutic targets for the prevention of future type 2 diabetes onset in morbidly obese patients. The present study evaluates the epigenetic basis of insulin resistance by performing a genome-wide epigenetic analysis in visceral adipose tissue from morbidly obese patients depending on the insulin sensitivity.
Translational Significance
The epigenome-wide analysis performed in this study identified a number of genes that could comprise an epigenetic signature of insulin resistance-related adipose tissue pathogenesis, providing for the first time new and valuable DNA methylation biomarkers of visceral adipose tissue pathogenesis that are associated with insulin resistance. Therefore, the observations of the current work are of foremost relevance as they provide tools for additional personalized treatment for prevention of type 2 diabetes. sensitivity were included in this study. We first evaluated a discovery cohort (n 5 5 insulin-sensitive (IS) and n 5 7 IR morbidly obese participants). An extended validation cohort composed of 24 morbidly obese Caucasian patients with different degrees of insulin sensitivity was analyzed (n 5 13 IS and n 5 11 IR). All participants were recruited at the Endocrinology Service of the University Hospital of Dr. Josep Trueta (Girona, Spain). All subjects confirmed that their body weight had been stable for $3 months before the study. Written informed consent to participate in the trial was obtained before the beginning of the study, in agreement with the Declaration of Helsinki, and the study was performed following the national and European Union guidelines. The protocol of this study was approved by the Hospital Ethics Committee.
VAT samples were obtained during elective surgical procedures (cholecystectomy, surgery for abdominal hernia and gastric bypass surgery), washed, and immediately flash-frozen in liquid nitrogen before being stored at 280 C. Anthropometric, biochemical determinations, and an euglycemic-hyperinsulinemic clamp for insulin action measurement were implemented as aforementioned. 17 Insulin resistance was defined by the M-values cutoff ,4.7.
18,19 DNA samples were isolated from 200 mg of VAT. The anthropometric and clinical characteristics of these subjects are shown in Table I Materials & methods) . DNA quality checks, bisulfite modification, hybridization, data normalization, statistical filtering, and b value calculations to assess the cytosine methylation states were performed as described elsewhere. 20, 21 Pyrosequencing was used to assess selected markers as aforementioned. 22 Pyrosequencing reactions and methylation quantification were performed in a PyroMark Q96 ID System (Qiagen) using appropriate reagents and protocols recommended by the manufacturer (details and primer sequences are available in the Supplementary Methods). Gene expression was assessed by real-time PCR using TaqMan technology suitable for relative gene expression quantification in a LightCycler 480 Real-Time PCR System (Roche Statistical analyses. Anthropometric and clinical characteristics of individuals are expressed as mean 6 standard deviation. Differences in these data between IR and IS patients were tested by unpaired Student t test. The methylation level of each cytosine was expressed as a b value calculated as the fluorescence intensity ratio of the methylated to the unmethylated versions of the probes. The b values ranged between 0 (unmethylated) and 1 (completely methylated) according to a combination of the Cy3 and Cy5 fluorescence intensities. Color balance adjustment and quantile normalization were performed to normalize the samples between the 2 color channels. b values with detection P-values .0.01 were considered to fall below the minimum intensity and threshold, and these values were consequently removed from further analysis. Approximately 96% of the CpG islands were covered, along with regions proximal to the CpG islands (''CpG shores'') and the more distal CpG shelves. In addition, the probes that were localized to the sex chromosomes and those considered single nucleotide polymorphisms were filtered out.
To identify consistent patterns of differentially methylated CpG sites (DMCpGs) between the IR and IS VAT samples, nonparametric Wilcoxon rank-sum tests were performed. P-values were adjusted for multiple comparisons using the false discovery rate procedure of Benjamini and Hochberg. In this analysis, a false discovery rate below 5% (q value) was considered statistically significant. However, given the sample size, we selected the raw P-values of , 0.05 as a less stringent cutoff for differential methylation than q values. In addition, we applied a threshold for the significant sites based on the mean differences between groups with a minimum b value change of 60.05. The P-values were represented in a Manhattan plot (2log10 of the P-value by genomic location). Hierarchical cluster analysis of the significant CpGs was performed using the heatmap function. The overall distribution of significant CpG sites compared with all analyzed sites on the Infinium HumanMethylation 450 BeadChip was analyzed using a chi-square test. All of the aforementioned statistical analyses were performed using R software (version 3.2.0).
To estimate the enrichment in biological processes, a hypergeometric test was performed on the biological processes defined by gene ontology (GO). 23 This analysis detected the significant over-representation of GO terms in one of the sets (ie, list of selected genes) with respect to the other for the entire genome. GO terms with an adjusted P-value of ,.05 were considered significant.
Differences in DNA methylation levels detected by pyrosequencing and expression of selected genes between groups were assessed by the nonparametric Mann-Whitney U test using the SPSS version 17.0 software (SPSS Inc, Chicago, Ill) for Windows XP (Microsoft, Redmond, Wash). P-values of # 0.05 were considered statistically significant.
RESULTS
Clinical characteristics of subjects with different degrees of insulin sensitivity. Thirty-six morbid obese patients were included in this study. The IS and IR individuals were matched for age, gender, and body mass index in both the discovery and the validation cohorts (Table I) . Statistically significant changes were observed in parameters associated with insulin resistance, such as waist circumference, HbA 1c , and lipid profile, in addition to differences in the M-clamp value, as expected by design (Table I) .
Differential DNA methylation in VAT from IR vs IS patients. Direct comparison of the average of methylation levels of the 447,104 valid CpGs revealed relatively similar global patterns between IR and IS (Supplemental Fig S1A) . The comparison of the DNA methylation levels between IR and IS obese VATs revealed 982 individual CpG sites that exhibit differential DNA methylation $5% (P , .05) between both groups (Supplemental Table S1 ). The change in DNA methylation of individual CpG sites with a significant difference between IR and IS (P , .05) ranged from 20.38 to 0.77 (Supplemental Fig S1B) , and most of the differentially methylated CpG sites (DMCpGs) presented absolute differences between 5% and 10%. No differences were observed in the average DNA methylation levels of the 982 individual DMCpG sites (Supplemental Fig S1C) . A Manhattan and a correlation plot between IR and IS patients are shown in Supplemental Figures S1D and S1E, respectively.
Genomic and chromosomal distribution of differentially methylated CpG sites in IR VAT. The 982 identified CpG sites were associated with 538 unique genes (Supplemental Table S1 ). The majority were located outside CpG-rich regions (CpG islands), mainly in the open-sea region ( Fig 1A) . Moreover, the identified CpG sites with altered levels of DNA methylation between IR and IS were enriched within the intergenic regions ( Fig 1B) . The CpG sites with decreased methylation levels in IR with respect to IS VAT were located in CpG islands and shores, whereas those with increased methylation levels were located in the opensea region (Supplemental Fig S1F) . The distribution of gain and diminution of methylation in IR with respect to that observed in IS samples was similar regarding the respective location relative to genes (Supplemental Fig S1G) . With respect to the chromosomic distribution of individual DMCpGs in IR compared with IS, those DMCpGs with increased methylation levels in IR were distributed in chromosomes 1, 5, 6, 10, 11, and 13, whereas those DMCpGs with decreased methylation levels in IR were mainly found in chromosomes 12, 16, and 19 (Supplemental Fig S1H) . Importantly, the identified CpG sites were able to perfectly differentiate the IR and IS samples using a hierarchical cluster approach ( Fig 1C) . Additional bioinformatics analysis of the differently methylated regions yielded information regarding the overlap of these regions with enhancers, DNase hypersensitive, and open chromatin regions. For that analysis, we exploited the state-of-the-art Epic Illumina manifest, which provides information of the chromosomal coordinates for this type of important gene regulatory feature. This information was determined by the ENCODE Consortium using informatics and the original 450K consortia members. This Epic updated manifest from Illumina contains 912 CpGs of the 980 DMCpGs in this study. Thus, among the 912 CpGs, 257 CpGs were located in enhancers, 541 were located in chromosomal coordinates of the DNase hypersensitive region, and 98 were located in chromosomal coordinates of open chromatin regions. Moreover, 247 CpGs of the 980 DMCpGs were located in promoters (Supplemental Table S1 ).
Biological significance of the CpG sites and the associated genes in IR. A GO analysis was performed to test whether certain molecular functions or biological processes were significantly associated with genes showing a difference in DNA methylation status between IR and IS. Thus, among the significantly enriched functional processes, the categories of cell adhesion, signal transduction, and regulation of transcription exhibited the largest number of genes (Fig 2A) . Relevantly, most of the genes differentially methylated were significantly (P , .001) related and joined with the insulin pathway (Fig 2B) . Moreover, we found 56 diabetes-associated genes according to the Human Diabetes Proteome Project that were represented by DMCpGs (Supplemental Table S2 ), 19 of which were located in promoter and island/shore regions (Table II) .
Regarding molecular functions or biological processes, among the genes associated with cell adhesion, CpG sites associated with COL9A1, COL11A2, and CD44 exhibited higher methylation levels in IR than in IS VAT, whereas CpG sites representing MUC4 and ADAM2 showed lower levels in IR than in IS (Fig 3A) . Diminished methylation levels were also observed in IR for genes involved in transcription function, such as PER3, GATA4, PRUMB, TXNIP1, and ZNF714. Moreover HOXC4, TET1, FOXD2, and NRBF2 exhibited increased methylation levels in IR with respect to those in IS (Fig 3B) . Including signal transduction function, the methylation levels of DMCpGs for TNFSF14 and ADCY9 were found to have diminished in IR, whereas those coded by IGF2R, CXCL12, CXCL13, FGF7, and FGF14 were found to have increased in IR with respect to IS (Fig 3C) . In addition, although not statistically significant in the GO analysis, genes with metabolic function were identified by DMCpGs such as RAMP1, MUC4, SULT1B1, HOX13, TBX5, FAMBA1, HADACM, and SCG3 (Fig 3D) .
A further analysis was performed by searching for those 450k array probes located in island/shore promoter regions with differences in absolute b values of $ 0.10 and P-values of #0.01. Under these conditions, 11 CpG sites were detected. Among those, ZNF714 was selected because it was the gene with the largest methylation fold change and was represented by 5 consecutive CpGs that were differentially methylated in the island/ shore promoter region (mean delta b 5 20.27; P 5 .010).
Methylation levels of ZNF714 in a validation cohort. We used pyrosequencing to evaluate further DNA methylation levels for ZNF714. Thus, the differences in the methylation levels of ZNF714 observed in the 450K array ( Fig 4A) were replicated by pyrosequencing in the same cohort (Fig 4B) . Importantly, the ZNF714 methylation pattern was further validated by pyrosequencing in an independent cohort (validation cohort, n 5 24; Table I ; Fig 4C) .
DNA methylation has previously been associated with transcription repression. 13 Accordingly, IR samples showed significantly (P 5 .04) higher expression levels of the gene ZNF714 (0.0102 6 0.0025) than IS (0.0052 6 0.0005), and this expression was associated with the DNA methylation levels of ZNF714 (Fig 4D) . These results suggest that the epigenetic regulation of this gene related to insulin sensitivity could have a relevant biologic function.
DISCUSSION
In the current work, the genome-wide DNA methylation profile of VAT from morbidly obese patients with insulin resistance was characterized, and potential DNA methylation signatures of this metabolic disorder were identified. This work demonstrates that VAT from patients with disturbances in the insulin sensitivity presents a specific DNA methylation pattern. DNA methylation was altered in 982 CpG sites encoding 538 unique genes with differences in beta values ranging from 20.4 to 0.8. The identified genes were associated with functions involved in cell adhesion, signal transduction, and regulation of transcription. Relevantly, most of the genes that were differentially methylated were joined with the insulin pathway. In fact, 10% of the genes encoded by the DMCpGs in IR were identified as diabetesassociated genes. Therefore, this study demonstrates that the link between the dysfunction of VAT and insulin resistance may be epigenetically regulated, providing a potential therapeutic target and biomarkers to counteract this process.
In an obese state, adipose tissue becomes dysfunctional. The tissue loses its capacity to store fatty acids and presents altered adipokine production. This condition contributes to the etiology of obesity-related metabolic complications such as insulin resistance. 9 To date, whether epigenetics play a role in adipose tissue dysfunction has remained unknown.
The present study adds new and complementary information to previous studies in relation to T2D and adiposity, supporting the potential role of epigenetics in the development of insulin-sensitivity disturbances in obesity. Previous studies have highlighted the importance of epigenetic regulation as a mechanism in the pathogenesis of T2D. 24 Detailed information concerning the DNA methylome in human pancreatic islets from T2D and nondiabetic patients has been provided. 14,25 Genome-wide DNA methylation studies in human skeletal muscle from individuals with or without a family history of T2D have also indicated differential methylation in genes involved in insulin signaling and muscle function. 26 Global methylation levels in subcutaneous adipose tissue are correlated with measures of fat distribution and glucose homeostasis. 15 Moreover, differential methylation has previously been observed in VAT of obese men discordant for metabolic syndrome. 16 However, to the best of our knowledge, the present study is the first to involve a DNA methylation genome-wide analysis in VAT from morbidly obese patients in relation to insulin resistance by classifying patients according to the gold-standard technique for evaluating insulin sensitivity.
The IR-related DMCpGs were distributed mainly in the intergenic and open-sea regions, in agreement with what has been previously reported in white adipose tissue 27, 28 and in isolated fat cells in relation to adiposity 29 and T2D 26 and metabolic syndrome. 16 The mean magnitude of the absolute differences in beta values was small, in line with that observed in previous studies of adipose tissue. 16, [29] [30] [31] Although previous studies have reported global hypomethylation associated with T2D, 24 in the present study no differences were observed in the global methylation levels between IR and IS morbidly obese patients. However, the differential methylation analysis between IR and IS patients revealed genes involved in pathways associated with the function of adipose tissue, such as cell adhesion, signal transduction, and regulation of transcription. Relevantly, in agreement with the role of VAT in insulin resistance and future T2D onset, a significant number of genes mapped by the DMCpGs between IR and IS were associated with the insulin pathway and belong to the list of genes related to T2D.
Regarding the mechanism involved in the obesityrelated dysregulation of adipose tissue, several lines of evidence suggest that the remodeling of the extracellular matrix, particularly collagens, is essential for adipocyte and adipose tissue expansion, which is dysregulated in an obese state. 32 In agreement with the epigenetic point of view of this proposal, because novel IR-related genes are epigenetically regulated in VAT, the current work reveals alterations in the methylation levels of collagenrelated genes such as COL9A1 and COL11A2 together with other genes included in the cell-adhesion category of functional processes, such as CD44, MUC4, and ADAM2. In addition, the analysis identified relevant genes mapped by more than 2 CpG sites that could play a crucial role in the development of IR induced by dysfunctional VAT, such as GATA4, TET1, ZNF714, ADCY9, TBX5, and HDACM. Among these, the transcription factor GATA4 has been studied in the cardiac system to promote hypertrophy and mediate the leptininduced vascular, 33 suggesting a putative role of this gene in hypertension associated with obesity. Moreover, it was discovered that the loss of intestinal GATA4 prevents diet-induced obesity, promotes insulin sensitivity, 34 and protects against diet-induced hepatic steatosis 34 in mice. TET1 is a demethylase that was shown to regulate epigenetically insulin-like growth factor 2 mRNA binding protein 1.
35 TBX5 is a developmental gene that presented 4 DMCpGs. The gene was identified as a regulator of preadipocyte proliferation and adipogenic differentiation in abdominal adipose tissue under epigenetic control. 36 The zinc finger protein 714 (ZNF714) exhibited the highest DNA methylation difference and was mapped by 5 DMCpGs located in island/shore and promoter regions. The gene was found to present lower methylation levels in IR than in IS patients in association with increased transcription levels. Even though the functional association with the development of IR or T2D remains to be elucidated, future exploration of the role of this gene could reveal a novel mechanism involved in the development of IR and T2D in line with other zinc finger proteins, which are associated with adipogenesis, 37, 38 T2D, or insulin resistance.
39,40
The strength of this study is that it was performed in a homogeneous population classified according to insulin sensitivity measured by the gold-standard technique for detecting dysregulation in insulin action. The relatively small sample size is a limitation of this study. Obtaining visceral adipose tissue from a homogeneous population of subjects in whom insulin action is measured using a euglycemic clamp remains a challenge. However, the statistical significance observed when using small populations typically indicates that there is a real difference between experimental groups. We decided to use P-values for differential methylation without correction for multiple testing because of the relatively small sample size. Therefore, the results should be interpreted cautiously. However, subsequent analyses were performed with highly stringent filters to gain consistent results, which were further validated in an independent cohort. Although the magnitude of the DNA methylation differences between groups could be considered small, these differences may have been observed because of the use of complex tissue instead of a single cell but also because the intergroup pathophysiological differences were within a narrow range of insulin action.
In conclusion, the present study demonstrates the existence of a specific methylome map associated with insulin resistance in VAT. This IR-related methylome exhibits a potential epigenetic regulation involved in the dysregulation of VAT that could predispose to insulin resistance and future T2D onset in morbidly obese patients. To the best of our knowledge, this study is the first to investigate the global methylome of VAT obtained from patients in the clinical setting of morbid obesity with and without insulin resistance. Further research based on the results obtained from this study will open new avenues for studying the role of VAT in driving insulin resistance and future T2D by identifying potential epigenetic biomarkers and novel therapeutic targets in the prevention and treatment of these metabolic disturbances. A.B. Crujeiras and A. Diaz-Lagares designed the experiments, analyzed the data, and wrote the manuscript. J. M. Moreno-Navarrete, J. Sandoval, D. Hervas, and A. Gomez analyzed the data. W. Ricart, F. F. Casanueva, and M. Esteller contributed to discussions and reviewed the manuscript. J. M. Fernandez-Real designed the experiments, contributed to discussions, and reviewed the manuscript. A.B. Crujeiras and J. M. Fernandez-Real are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have reviewed and approved the article and have read the journal's authorship agreement.
APPENDIX SUPPLEMENTARY METHODS
DNA preparation and bisulfite conversion. DNA from fresh-frozen (FF) tissue samples was isolated using a standard phenol-chloroform/proteinase-k protocol. After proteinase-K incubation, adipose tissue homogenates were centrifuged (13000 g, 2 C, 30 min) to avoid lipid interference in the DNA purification process. The obtained DNA was treated with RNase A for 1 hour at 45 C. All DNA samples were quantified using the fluorometric method (Quan-iT PicoGreen DsDNA Assay, Life Technologies) and were assessed for purity using a NanoDrop (Thermo Scientific) with 260/280 and 260/230 ratio measurements. The integrity of the FF DNA was verified by electrophoresis in 1.3% agarose gel. FF DNA (600 ng) was processed using the EZ-96 DNA Methylation kit (Zymo Research Corp.) following the manufacturer's recommendations for Infinium assays.
DNA methylation analysis.
Infinium Human Methylation 450 BeadChip array. Microarray-based DNA methylation analysis was conducted with the Infinium Human Methylation 450 BeadChip (450K array). DNA quality checks, bisulfite modification, hybridization, data normalization, statistical filtering, and b value calculations were performed as described elsewhere. 20 High-quality DNA samples obtained from subcutaneous adipose tissue and leukocytes were selected for bisulfite conversion (Zymo Research; EZ-96 DNA Methylation Kit) and hybridization to the Infinium Human Methylation 450 BeadChips (Illumina) following the Illumina Infinium HD methylation protocol. The DNA concentration of the quality-control sample standards was measured using the PicoGreen method (Invitrogen) coupled with assessments of DNA purity based on the A260/A280 ratio (ranging between 1.75 and 1.95) and the A260/A230 ratio (ranging between 2.00 and 2.20). Analysis with 1% agarose gel electrophoresis allowed for the exclusion of samples with possible DNA fragmentation or RNA contamination. The Infinium Human Methylation 450 BeadChip provides coverage of .450,000 CpG sites targeting nearly all of the RefSeq genes (.99%). 20 The chips were designed to cover the coding and noncoding genes without bias against those lacking CpG islands. The design further aimed to cover not only promoter regulatory regions but also CpGs across gene regions to include the 5 0 -untranslated regions, the first exons, the gene bodies, and the 3 0 -untranslated regions. In total, 600 ng from the high-quality DNA samples was bisulfite converted. Whole-genome amplification and hybridization were then performed on the BeadChip and followed by single-base extension and analysis on a HiScan SQ module (Illumina) to assess the cytosine methylation states. The annotation of the CpG islands (CGI) involved the following categorization 1 : shore, for each of the 2-Kb sequences flanking a CGI 2 ; shelf, for each of the 2-kb sequences next to a shore; and 3 open sea, for DNA not included in any of the previous sequences or in CGIs. 21 The transcription start site 200 and the transcription start site 1500 indicate the regions either 200 or 1500 bp from the transcription start site, respectively.
Pyrosequencing analysis. Pyrosequencing was used to assess selected markers as previously described. 22 The primer sequences used in this analysis were designed using Qiagen's PyroMark Assay Design 2.0 software to hybridize to CpG-free sites to ensure methylation-independent amplification. Briefly, polymerase chain reaction (PCR) was performed using standard conditions with biotinylated primers, and the PyroMark Vacuum Prep Tool (Biotage, Uppsala, Sweden) was used to prepare single-stranded PCR products according to the manufacturer's instructions. Pyrosequencing reactions and methylation quantification were performed in a PyroMark Q96 System version 2.0.6 (Qiagen), using appropriate reagents and recommended protocols. The primer sequences used were (all given 5 0 . Gene expression analyses. Briefly, RNA purification was performed using the RNeasy Lipid Tissue Mini Kit (Qiagen, Izasa SA, Barcelona, Spain), and the integrity was verified using an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, Calif). Gene expression was assessed by real-time PCR using TaqMan technology suitable for relative genetic-expression quantification in a LightCycler 480 Real-Time PCR System (Roche Diagnostics SL, Barcelona, Spain). The RT-PCR reaction was performed in a final volume of 12 ml. The cycle program consisted of an initial denaturing of 10 minutes at 95 C and then 40 cycles of 15 seconds denaturizing phase at 95 C and a 1 minute annealing and extension phase at 60 C. A threshold cycle (Ct value) was obtained for each amplification curve, and a DCt value was first calculated by subtracting the Ct value for human peptidylprolyl isomerase A (cyclophilin A; PPIA) RNA from the Ct value for each sample. Fold changes relative to the endogenous control were then determined by calculating 22DCt; therefore, geneexpression results are expressed as the expression ratio relative to PPIA gene expression according to the manufacturers' guidelines. The commercially available and prevalidated TaqMan primer/probe sets used were as follows: PPIA (4333763, endogenous control) and zinc finger protein 714 (ZNF714, Hs02743732_s1; Life Technologies S.A., Madrid, Spain). Supplementary Fig 1. 
